FILE:BMY/BMY-8K-20070618162942.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (General Instruction A.2. below):
see
 
 
 
 
 
On June 15, 2007, Bristol-Myers Squibb Company (the "Company") confirmed that the Deferred Prosecution Agreement ("DPA") entered into between the Company and the U.S. Attorney's Office for the District of New Jersey ("USAO") on June 15, 2005 expired June 15, 2007. The USAO has informed the Company that, as contemplated by the DPA, it will seek within ten days a dismissal with prejudice of the criminal complaint filed by the USAO relating to wholesaler inventory and various accounting matters. As required under the DPA, the Company will continue to cooperate in connection with pending matters being pursued by the USAO.
On June 14, 2007, the Company issued a press release relating to the expiration of the deferred prosecution agreement. A copy of the press release is filed as Exhibit 99.1 to this report.
 
(d) Exhibits.
      99.1    Press release of Bristol-Myers Squibb Company dated June 14, 2007
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

Exhibit 99.1
 
Laura Hortas
Communications
(609) 252-4587
laura.hortas@bms.com
Tony Plohoros
Communications
(609) 252-7938
tony.plohoros@bms.com
June 14, 2007  (NEW YORK)  Bristol-Myers Squibb today acknowledged the statement by the Hon. Christopher J. Christie, the U.S. Attorney for the District of New Jersey, regarding tomorrow's expiration of the deferred prosecution agreement (DPA).
During the past two years, Bristol-Myers Squibb has complied with the letter and spirit of the DPA and has made significant enhancements to its compliance structures and practices. The company believes its business operations are stronger today as a result of having embraced a culture of compliance. The expiration of the DPA will not diminish the company's commitment to exemplary corporate citizenship, effective corporate governance practices and the highest principles of integrity and professionalism.
Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.


